Hosted on MSN1mon
BTIG Downgrades Keros Therapeutics (KROS)
Fintel reports that on December 12, 2024, BTIG downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from Buy to Neutral. Analyst Price Forecast Suggests 408.15% Upside As of December 3 ...
Business Insider1mon
TD Cowen downgrades Keros Therapeutics (KROS) to a Hold
Keros Therapeutics (KROS – Research Report) received a Hold rating and price target from TD Cowen analyst Tyler Van Buren today. The company’s shares opened today at $18.71. Pick the best ...